Shelton Capital Management Sarepta Therapeutics, Inc. Transaction History
Shelton Capital Management
- $3.62 Billion
- Q2 2024
A detailed history of Shelton Capital Management transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Shelton Capital Management holds 3,818 shares of SRPT stock, worth $487,787. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,818Holding current value
$487,787% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding SRPT
# of Institutions
558Shares Held
85.8MCall Options Held
3.67MPut Options Held
1.75M-
Black Rock Inc. New York, NY10.3MShares$1.32 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.15 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$552 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$529 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$487 Million0.33% of portfolio
About Sarepta Therapeutics, Inc.
- Ticker SRPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 87,567,904
- Market Cap $11.2B
- Description
- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...